Research progress of m6A methylation modification in ocular diseases
10.3980/j.issn.1672-5123.2024.4.18
- VernacularTitle:m6A甲基化修饰在眼科疾病中的研究进展
- Author:
Yuyu XUE
1
,
2
;
Chunmeng LIU
1
,
2
;
Jie CHEN
1
,
2
;
Hejiang YE
1
,
2
Author Information
1. Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China
2. Department of Ophthalmology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China
- Publication Type:Journal Article
- Keywords:
N6-methyladenosine(m6A);
RNA methylation;
diabetic retinopathy;
cataract;
age-related macular degeneration;
uveal melanoma
- From:
International Eye Science
2024;24(4):589-595
- CountryChina
- Language:Chinese
-
Abstract:
N6-methyladenosine(m6A), the most common, abundant, and conserved RNA modification in eukaryotic cells, regulates RNA splicing, stability, output, degradation and translation through m6A methyltransferase, m6A demethylase, and m6A methylated binding proteins. Recent studies have found that abnormal m6A methylation may mediate a variety of pathological processes in eyes and participate in the occurrence and development of metabolic, inflammatory, degenerative ocular diseases and ocular tumors, such as diabetic retinopathy, cataract, age-related macular degeneration and uveal melanoma. This review aims to summarize the roles of m6A methylation modification in ocular cells and ocular diseases, elucidate the potential molecular mechanisms of m6A methylation in ocular diseases, so as to encourage innovative approaches in the treatment of these ocular diseases.
